83 related articles for article (PubMed ID: 11019426)
1. [Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy].
Golenkov AK; Trifonova EV; Kataeva EV; Kil'diushevskiĭ AV; Lutskaia TD; Zariad'eva EA; Nazarova IN; Lukashina MN; Zabotina TN; Mikhaĭlova IN; Inshakov AN; Logacheva NP; Baryshnikov AIu
Ter Arkh; 2000; 72(8):38-41. PubMed ID: 11019426
[TBL] [Abstract][Full Text] [Related]
2. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Sher T; Miller KC; Lee K; Chanan-Khan A
Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
[TBL] [Abstract][Full Text] [Related]
4. The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Horak P; Minarik J
Haematologica; 2005 Dec; 90(12):1713-4. PubMed ID: 16330455
[TBL] [Abstract][Full Text] [Related]
5. [A case of aggressive myeloma with abnormal plasmocytes in pleural effusion and cerebrospinal fluid].
Sekikawa T; Iwase S; Kawano T; Takahara S; Ito K; Yamada J; Yamazaki Y; Yamada H
Rinsho Ketsueki; 1999 Jan; 40(1):22-7. PubMed ID: 10067092
[TBL] [Abstract][Full Text] [Related]
6. Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells.
Ludwig H; Fritz E
Anticancer Res; 1981; 1(6):329-34. PubMed ID: 7344610
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
10. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
[TBL] [Abstract][Full Text] [Related]
11. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
12. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
13. Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
Gola A; Kuliczkowski K; Sedek K
Neoplasma; 1992; 39(1):35-8. PubMed ID: 1528303
[TBL] [Abstract][Full Text] [Related]
14. [Changes of electrocoagulographic parameters and erythrocyte deformability in multiple myeloma patients on various regimens of polychemotherapy].
Bessmel'tsev SS; Katsadze IuL
Klin Med (Mosk); 1991 Nov; 69(11):69-73. PubMed ID: 1808414
[TBL] [Abstract][Full Text] [Related]
15. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
D'Sa S; Yong K; Kyriakou C; Bhattacharya S; Peggs KS; Foulkes B; Watts MJ; Ings SJ; Ardeshna KM; Goldstone AH; Williams CD
Br J Haematol; 2004 Jun; 125(6):756-65. PubMed ID: 15180865
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
17. [Combination chemotherapy in Alkeran-resistant myelomatosis].
Kjølseth I; Wisløff F; Godal HC
Tidsskr Nor Laegeforen; 1984 May; 104(13):873-4. PubMed ID: 6463973
[No Abstract] [Full Text] [Related]
18. Unusual morphologic presentation of plasma cells during the course of a multiple myeloma.
Salignac S; Buisine J; Lesesve JF
Haematologica; 2004 Apr; 89(4):EIM04. PubMed ID: 15075107
[No Abstract] [Full Text] [Related]
19. Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.
Izzi T; Polchi P; Moretti L; Lucarelli G
Haematologica; 1983; 68(3):381-91. PubMed ID: 6411532
[No Abstract] [Full Text] [Related]
20. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
Abdulkadyrov KM; Bessmel'tsev SS
Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
[No Abstract] [Full Text] [Related]
[Next] [New Search]
